Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jonathan Temte MD, PhD
Jonathan Temte MD, PhD Advisory Board
Robert Bonakdar MD, FAAFP, FACN
Robert Bonakdar MD, FAAFP, FACN Advisory Board
Irene Hamrick MD, FAAFP, AGSF, CMD
Irene Hamrick MD, FAAFP, AGSF, CMD Advisory Board
See All Experts
story of the week
Published in Primary Care

Journal Scan / Research · January 09, 2014

IBIS II Results: Breast Cancer Prevention in High-Risk Women With Anastrozole

The Lancet

 

 Save  Recommend
 Share

Additional Info

The Lancet
Anastrozole for Prevention of Breast Cancer in High-Risk Postmenopausal Women (IBIS-II): An International, Double-Blind, Randomised Placebo-Controlled Trial
Lancet 2013 Dec 12;[EPub Ahead of Print], J Cuzick, I Sestak, JF Forbes, M Dowsett, J Knox, S Cawthorn, C Saunders, N Roche, RE Mansel, G von Minckwitz, B Bonanni, T Palva, A Howell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated